Although previous reports suggest some chemotherapeutic agents do not affect surface marker expression, proliferation and differentiation of AD-MSCs [54], it is not known whether cancer and/or subsequent cancer treatment causes long-term alterations in the expression and function of purinergic receptors in these cells. The gene discussed is P2RX3; the disease is cancer.